Get started
Author

Fraser D. Johnson

Observed names: F.D. Johnson, Fraser D. Johnson, Fraser D Johnson, Fraser Johnson, Johnson, Fraser
ORCID: 0000-0003-2253-7186
Observed ORCID: 0000-0003-2253-7186
OpenAlex ID: A5029917783
The Master Neural Transcription Factor BRN2 Is an Androgen Receptor–Suppressed Driver of Neuroendocrine Differentiation in Prostate Cancer
2016 · Jennifer L. Bishop, Daksh Thaper, et al. · Cancer Discovery · 419
SMARCA4/2 loss inhibits chemotherapy-induced apoptosis by restricting IP3R3-mediated Ca2+ flux to mitochondria
2021 · Yibo Xue, Jordan L. Morris, et al. · Nature Communications · 76
PDF
Epithelial tumor suppressor ELF3 is a lineage-specific amplified oncogene in lung adenocarcinoma
2019 · Katey S. S. Enfield, Erin A. Marshall, et al. · Nature Communications · 68
PDF
CCL5 production in lung cancer cells leads to an altered immune microenvironment and promotes tumor development
2021 · Etienne S. Melese, Elizabeth Franks, et al. · OncoImmunology · 61
PDF
Extracellular signal-regulated kinase mediates chromatin rewiring and lineage transformation in lung cancer
2021 · Yusuke Inoue, Ana Nikolic, et al. · eLife · 37
Combined AKT and MEK Pathway Blockade in Pre-Clinical Models of Enzalutamide-Resistant Prostate Cancer
2016 · Paul Toren, Soojin Kim, et al. · PLoS ONE · 33
PDF
Characterization of a small molecule inhibitor of disulfide reductases that induces oxidative stress and lethality in lung cancer cells
2022 · Fraser D. Johnson, John Ferrarone, et al. · Cell Reports · 32
PDF
MEK inhibitor resistance in lung adenocarcinoma is associated with addiction to sustained ERK suppression
2022 · Dylan A. Farnsworth, Yusuke Inoue, et al. · npj Precision Oncology · 20
PDF
Methionine-producing tumor micro(be) environment fuels growth of solid tumors
2023 · Alexis A. Vega, Erin A. Marshall, et al. · Cellular Oncology · 18
PDF
Tandem mass tag-based thermal proteome profiling for the discovery of drug-protein interactions in cancer cells
2023 · Fraser D. Johnson, Christopher S. Hughes, et al. · STAR Protocols · 10
HACE1 blocks HIF1α accumulation under hypoxia in a RAC1 dependent manner
2021 · Busra Turgu, Fan Zhang, et al. · Oncogene · 9
PDF
Loss of ATG4B and ATG4A results in two-stage cell cycle defects in pancreatic ductal adenocarcinoma cells
2023 · Paalini Sathiyaseelan, Suganthi Chittaranjan, et al. · Journal of Cell Science · 6
MHC1-TIP enables single-tube multimodal immunopeptidome profiling and uncovers intratumoral heterogeneity in antigen presentation
2026 · Mayukha Bathini, Diana Bocaniciu, et al. · Communications Biology · 2
PDF
Characterizing the secretome of EGFR mutant lung adenocarcinoma
2024 · Jennifer K. Luu, Fraser D. Johnson, et al. · Frontiers in Oncology · 2
PDF
Targeting adenocarcinoma and enzalutamide‑resistant prostate cancer using the novel anti‑androgen inhibitor ADA‑308
2024 · Shaghayegh Nouruzi, Fraser Johnson, et al. · Oncology Reports · 1
PDF
Author Correction: SMARCA4/2 loss inhibits chemotherapy-induced apoptosis by restricting IP3R3-mediated Ca2+ flux to mitochondria
2023 · Yibo Xue, Jordan L. Morris, et al. · Nature Communications · 1
PDF
MEK inhibitor resistance in lung cancer cells associated with addiction to sustained ERK suppression
2022 · Dylan A. Farnsworth, Yusuke Inoue, et al. · bioRxiv (Cold Spring Harbor Laboratory) · 1
PDF
A novel small molecule that induces cytotoxicity in lung cancer cells inhibits disulfide reductases GSR and TXNRD1
2021 · Fraser D. Johnson, John Ferrarone, et al. · bioRxiv (Cold Spring Harbor Laboratory) · 1
PDF
Author response: Extracellular signal-regulated kinase mediates chromatin rewiring and lineage transformation in lung cancer
2021 · Yusuke Inoue, Ana Nikolic, et al. · 1
The Plasticity of Stem-Like States in Patient-Derived Tumor Xenografts
2017 · Alastair H. Davies, Fraser Johnson, et al. · Molecular and translational medicine · 1
EP.02.03 Investigating the Therapeutic Potential of DUSP4/6 Inhibition in Lung Adenocarcinoma
2025 · A. Subramaniam, D.A. Farnsworth, et al. · Journal of Thoracic Oncology
Supplementary Figure S1 - S8 from The Master Neural Transcription Factor BRN2 Is an Androgen Receptor–Suppressed Driver of Neuroendocrine Differentiation in Prostate Cancer
2023 · Jennifer L. Bishop, Daksh Thaper, et al.
PDF
Supplementary Methods, Figure Legends from The Master Neural Transcription Factor BRN2 Is an Androgen Receptor–Suppressed Driver of Neuroendocrine Differentiation in Prostate Cancer
2023 · Jennifer L. Bishop, Daksh Thaper, et al.
PDF
Supplementary Table S1 from The Master Neural Transcription Factor BRN2 Is an Androgen Receptor–Suppressed Driver of Neuroendocrine Differentiation in Prostate Cancer
2023 · Jennifer L. Bishop, Daksh Thaper, et al.
Supplementary Table S4 from The Master Neural Transcription Factor BRN2 Is an Androgen Receptor–Suppressed Driver of Neuroendocrine Differentiation in Prostate Cancer
2023 · Jennifer L. Bishop, Daksh Thaper, et al.
Works count: 41
Citation count: 799
H-index: 10
I10-index: 10
Year
Topic
Type